Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| secretory cell | 5 studies | 26% ± 7% | |
| club cell | 3 studies | 27% ± 9% | |
| basal cell | 3 studies | 23% ± 5% |
Insufficient scRNA-seq data for expression of CXCL6 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 84% | 278.33 | 276 / 328 | 80% | 26.61 | 143 / 178 |
| prostate | 91% | 275.45 | 222 / 245 | 44% | 4.01 | 220 / 502 |
| kidney | 83% | 271.10 | 74 / 89 | 49% | 27.80 | 438 / 901 |
| liver | 84% | 199.40 | 190 / 226 | 38% | 26.42 | 155 / 406 |
| lung | 57% | 212.20 | 327 / 578 | 55% | 23.12 | 632 / 1155 |
| esophagus | 29% | 72.29 | 413 / 1445 | 75% | 27.18 | 138 / 183 |
| spleen | 100% | 5018.56 | 241 / 241 | 0% | 0 | 0 / 0 |
| intestine | 39% | 68.47 | 375 / 966 | 49% | 9.20 | 258 / 527 |
| stomach | 19% | 18.03 | 70 / 359 | 47% | 10.07 | 134 / 286 |
| uterus | 7% | 17.48 | 12 / 170 | 51% | 26.95 | 234 / 459 |
| bladder | 14% | 18.81 | 3 / 21 | 43% | 11.76 | 218 / 504 |
| adipose | 37% | 206.09 | 443 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 36% | 12.82 | 16 / 45 |
| ovary | 8% | 3.51 | 14 / 180 | 27% | 3.27 | 117 / 430 |
| skin | 28% | 670.19 | 509 / 1809 | 5% | 0.73 | 24 / 472 |
| heart | 32% | 111.02 | 278 / 861 | 0% | 0 | 0 / 0 |
| breast | 27% | 25.65 | 122 / 459 | 5% | 0.58 | 53 / 1118 |
| peripheral blood | 13% | 19.01 | 122 / 929 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 10% | 1.30 | 3 / 29 |
| brain | 2% | 1.21 | 52 / 2642 | 7% | 1.52 | 49 / 705 |
| thymus | 2% | 1.45 | 16 / 653 | 6% | 1.18 | 39 / 605 |
| blood vessel | 9% | 9.73 | 117 / 1335 | 0% | 0 | 0 / 0 |
| adrenal gland | 7% | 6.53 | 17 / 258 | 1% | 0.31 | 3 / 230 |
| muscle | 0% | 0.30 | 1 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0001776 | Biological process | leukocyte homeostasis |
| GO_0006954 | Biological process | inflammatory response |
| GO_0007165 | Biological process | signal transduction |
| GO_0030593 | Biological process | neutrophil chemotaxis |
| GO_0006935 | Biological process | chemotaxis |
| GO_0007267 | Biological process | cell-cell signaling |
| GO_0070098 | Biological process | chemokine-mediated signaling pathway |
| GO_0042742 | Biological process | defense response to bacterium |
| GO_0071222 | Biological process | cellular response to lipopolysaccharide |
| GO_0061844 | Biological process | antimicrobial humoral immune response mediated by antimicrobial peptide |
| GO_0070951 | Biological process | regulation of neutrophil mediated killing of gram-negative bacterium |
| GO_0042119 | Biological process | neutrophil activation |
| GO_0032642 | Biological process | regulation of chemokine production |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0008201 | Molecular function | heparin binding |
| GO_0008009 | Molecular function | chemokine activity |
| GO_0045236 | Molecular function | CXCR chemokine receptor binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CXCL6 |
| Protein name | C-X-C motif chemokine 6 (Chemokine alpha 3) (CKA-3) (Granulocyte chemotactic protein 2) (GCP-2) (Small-inducible cytokine B6) [Cleaved into: Small-inducible cytokine B6, N-processed variant 1; Small-inducible cytokine B6, N-processed variant 2; Small-inducible cytokine B6, N-processed variant 3] C-X-C motif chemokine |
| Synonyms | SCYB6 GCP2 |
| Description | FUNCTION: Chemotactic for neutrophil granulocytes. Signals through binding and activation of its receptors (CXCR1 and CXCR2). In addition to its chemotactic and angiogenic properties, it has strong antibacterial activity against Gram-positive and Gram-negative bacteria (90-fold-higher when compared to CXCL5 and CXCL7). . |
| Accessions | P80162 D6RF92 ENST00000515050.1 ENST00000226317.10 |